Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/3369
Full metadata record
DC FieldValueLanguage
dc.contributor.advisorMasiá Canuto, María del Mar-
dc.contributor.authorTerol Esclápez, Gertrudis-
dc.date.accessioned2017-02-27T11:52:03Z-
dc.date.available2017-02-27T11:52:03Z-
dc.date.created2015-09-16-
dc.date.issued2017-02-27-
dc.identifier.urihttp://hdl.handle.net/11000/3369-
dc.description.abstractBACKGROUND: CD4/CD8 ratio is a potential marker of immune activation and risk of developing non- AIDS events. A low ratio is associated with persistent chronic immune dysfunction, T cell activation and immune senescence. An optimal response to antirretroviral (AVR) therapy requires normalization of CD4/CD8 ratio, but this only occurs in a minority of patients. END POINT: To determine the evolution of CD4/CD8 ratio in HIV patients on effective AVR therapy in relation to the different ARV regimens used and whether there are differences among them or not. METHODS: A cohort of HIV patients from 1980-2014 is analyzed, receiving suppressor regimens based on non-nucleoside reverse-transcriptase inhibitors (NNRTI), Protease Inhibitors (PI) or integrase inhibitors (II) with a duration of at least 6 months and a CD4/CD8 ratio ≤ 1, at the begining of the different each regimen. RESULTS: There were 880 treatment regimens studied, incluiding 502 patients with a mean age of 41.95 years, mostly men (78.49%) of Spanish nationality (81.28%). The HIV infection risk factors were: 46.02% users of intravenous drugs, 23.51% homosexuals and 22.51% heterosexuals. Hepatitis C co-infection, was found in %. Broadly, with each treatment regimen, there is a trend towards and increase of the CD4 / CD8 ratio during the follow up, and a minority of patiens have achieved the goal of normalization (ratio ≥ 1). The different treatment regimens, seem to determine a different evolution of the cd4/cd8 ratio, observing a better trend with the II regimen, but these data are yet to be analyzed . CONCLUSIONS: Finding differences among ARV regimens, could contribute to develop better therapies targeting immune restoration in HIV patients.es
dc.formatapplication/pdfes
dc.format.extent13es
dc.language.isospaes
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.subjectCociente CD4/CD8, VIH, Tratamiento antirretroviral, Linfocitoses
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicinaes
dc.titleInfluencia sobre la evolución del cociente CD4/CD8 de la utilización de distintas pautas de tratamiento antirretrovirales
dc.typeinfo:eu-repo/semantics/masterThesises
Appears in Collections:
TFM-M.U Enfermedades Infecciosas y Salud Internacional


Thumbnail

View/Open:
 TEROL ESCLAPEZ, GERTRUDIS.pdf
267,88 kB
Adobe PDF
Share:


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.